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Abstract
Type 2 diabetes mellitus increases the risk of atherosclerotic cardiovascular disease. 
Anti-oxidative properties of HDL are important for athero-protection. The present 
study investigated whether the anti-oxidative functionality of HDL is altered in type 2 
diabetes mellitus and aimed to identify potential determinants of this parameter. 
In a cross-sectional study we investigated 74 type 2 diabetic patients and 75 control 
subjects. Anti-oxidative properties of HDL were measured and expressed as either 
(i) HDL anti-oxidative capacity or (ii) HDL anti-oxidation index after multiplying 
HDL anti-oxidative capacity results with individual plasma HDL cholesterol 
concentrations. Lecithin-cholesterol acyltransferase (LCAT) and paraoxonase-1 
(PON-1) activities were determined. 
HDL anti-oxidative capacity was similar in diabetic patients and controls, while 
the HDL anti-oxidation index was decreased in diabetics (P=0.005) due to lower 
plasma HDL cholesterol (P<0.001). LCAT activity was higher and PON-1 activity 
lower in type 2 diabetes mellitus (each P<0.001). In the combined subjects, HDL 
anti-oxidative capacity was inversely related to LCAT activity (P<0.01). The HDL 
anti-oxidation index correlated negatively with blood glucose (P<0.001), HbA1c and 
LCAT activity (each P<0.01) and positively with PON-1 activity (P<0.01). Multiple 
linear regression analysis demonstrated that high LCAT activity was associated 
with both decreased HDL anti-oxidation capacity (P<0.05) and index (P<0.001) 
independent of diabetes status, glycemic control and PON-1.
In conclusion, overall anti-oxidative functionality of HDL is impaired in type  2 
diabetes mellitus mostly due to lower HDL cholesterol. Hyperglycemia, increased 





Large population studies demonstrated that plasma levels of HDL cholesterol confer 
protection against atherosclerotic cardiovascular disease (CVD) (1;2). However, 
some patients experience CVD events despite high levels of HDL cholesterol, 
while conversely a certain percentage of individuals with low HDL remains free 
of CVD  (1-3). In addition, especially in patient populations with an increased 
inflammatory load the inverse relationship between plasma HDL cholesterol levels 
and the incidence of CVD events is lost (4;5). Such observations led to the emerging 
concept that HDL quality might be an important contributing factor to individual 
CVD risk (3;6;7). Therefore, additional clinically relevant information might be 
derived from assays specifically designed to test distinct functional aspects of HDL.
Patients with type 2 diabetes mellitus have an increased CVD morbidity and 
mortality  (8-11). This is partly attributable to a pro-atherogenic plasma lipid and 
lipoprotein profile with increased total cholesterol and triglyceride levels and 
decreased HDL cholesterol (8;11). In addition, in vivo oxidative stress, inflammatory 
load as well as circulating levels of oxLDL are higher in type 2 diabetes mellitus patients 
compared with controls (12). An important functional feature of HDL is protection 
of LDL from oxidative modification (3;6;7). Mainly two enzymes associated with 
HDL, namely paraoxonase-1 (PON-1) and lecithin-cholesterol acyltransferase 
(LCAT), have thus far been implicated in the anti-oxidative protection capacity 
of HDL particles (13), and the activities of both are changed in type 2 diabetic 
patients (14;15). Altered HDL functionality might therefore conceivably contribute 
to the increased CVD risk in type 2 diabetes mellitus patients. However, still little is 
known about changes in HDL function in diabetic patients (16;17). Therefore, the 
aim of the present study was to compare the anti-oxidative functionality of HDL 
between diabetic patients and control subjects and also to identify factors impacting 
on this key atheroprotective property of HDL. 
Our results indicate that the anti-oxidative function of HDL per se is not diminished 
in diabetic patients. However, the total HDL-mediated anti-oxidative protection 
capacity is lower due to decreased plasma HDL cholesterol levels. In addition, our 
study reveals that impaired glycemic control and increased LCAT activity are major 





The study protocol was approved by the Medical Ethics Committee of the University 
Medical Center Groningen, The Netherlands, and written informed consent was 
obtained from all subjects. Reporting of the study conforms to the STROBE statement 
and the broader EQUATOR guidelines (18). The study was performed in a university 
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hospital setting. The participants (aged > 18 years) were recruited by advertisement 
and provided written informed consent before entering the study. Type 2 diabetes 
mellitus was previously diagnosed by primary care physicians using glucose cut-off 
values as defined by the World Health Organization (19). The medical history of the 
participants did not demonstrate recent illnesses, and there were no pulmonary or 
cardiac abnormalities on physical examination. Clinically manifest cardiovascular 
disease, renal function abnormalities (elevated serum creatinine and/or elevated 
urinary albumin excretion), urinary tract infection (positive urine dipstick for 
leukocytes or blood) were exclusion criteria, as were current smoking, the use of > 
3 alcoholic beverages per day and the current use of lipid lowering drugs. Diabetic 
patients using insulin were also excluded, while antihypertensive medication was 
permitted. A total of 74 type 2 diabetes mellitus patients (median diabetes duration 
5 years (interquartile range 4 to 6 years) and 75 control subjects were included in the 
study. Systolic and diastolic blood pressure were measured after 15 min at rest with 
a sphygmomanometer in seated position and BMI was calculated as weight divided 
by height squared, given in kg/m2). All subjects were studied after an overnight fast.
Laboratory analyses
Venous blood samples were collected into EDTA-containing tubes (1.5 mg/ml) for 
the measurement of plasma lipids, apolipoproteins, insulin and the anti-oxidative 
capacity of HDL, whereas serum was obtained for measurement of PON-1 activity. 
Plasma and serum samples were prepared by centrifugation at 1400 g for 15 min at 
4 0C. Blood glucose and glycated hemoglobin (HbA1c) levels were measured directly 
after blood collection. Samples for other assays were stored at -80 0C until analysis.
Plasma cholesterol and triglycerides were assayed by routine enzymatic methods 
(Roche/Hitachi cat. Nos. 11876023 and 11875540 respectively, Roche Diagnostics 
GmbH, Mannheim, Germany). HDL cholesterol was measured using a homogeneous 
enzymatic colorimetric test (Roche/Hitachi cat. no. 03030024). Non-HDL cholesterol 
was calculated by subtracting HDL cholesterol from plasma total cholesterol. 
Apolipoprotein (apo) A-I and B were assayed by immunoturbidimetry (Roche/
Cobas Integra Tina-quant cat. no. 03032566 and 033032574, respectively, Roche 
Diagnostics).
To determine the anti-oxidative properties of HDL, apoB-containing lipoproteins were 
precipitated by adding 75 µl polyethylene glycol (PEG) 6000 in 10mM HEPES (pH 
8.0) to 150 µl of plasma followed by mixing and an incubation on ice for 30 minutes. 
Then, samples were centrifuged at 2000x g at 4˚C for 30 minutes. Supernatants were 
transferred to clean tubes and HDL-cholesterol concentrations were determined 
using a commercially available kit (Roche Diagnostics, Mannheim, Germany). Native 
LDL was isolated from a young healthy normolipidemic donor by density gradient 
ultracentrifugation (1.019<d<1.063) as described (20). To determine HDL-mediated 
protection against LDL oxidation, a previously published method was used (21). 
All samples were processed and assayed on the same day using identical reagents. 
Briefly, individual HDL preparations (0.26 mmol/l cholesterol), isolated as detailed 
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above, were added to aliquots of native LDL (1.95 mmol/l cholesterol) followed by 
the addition of 2,2’-Azobis(2-methylpropionamidine) dihydrochloride (AAPH, 
Cayman Chemicals, Ann Arbor, MI, USA) in a final concentration of 1 mM in a total 
volume of 110 µl. Samples were then incubated for 24 hours at 37 0C to induce LDL 
oxidation. Thiobarbituric acid reactive substances (TBARS) were determined as a 
measure for the degree of LDL oxidation (20). Briefly, 200 µl 10% trichloroacetic acid 
(TCA) was added to 100 µl sample and incubated on ice for 15 min. Subsequently, 
the mixtures were centrifuged at 2200x g at 4  0C for 15 min. Then 200 µl of the 
supernatant was transferred to new reaction tubes and 200 µl 0.67% thiobarbituric 
acid (TBA) was added to each sample. These mixtures were incubated in a boiling 
waterbath for 10 min and cooled down on ice. Then, fluorescence was measured 
and the amounts of TBARS in the samples were calculated using a standard curve. 
The HDL anti-oxidative capacity (AOCap) was calculated as the difference between 
the maximal amount of TBARS formed in a reaction to which no HDL had been 
added and the percent reduction obtained with an individual HDL sample. Thereby, 
higher values indicate better protection against oxidation. The intra-assay CV of 
HDL-AOCap amounts to 5.1%. The HDL anti-oxidation index (AOI) as global 
measure of the HDL-mediated protection capacity against oxidation was calculated 
by multiplying the HDL-AOCap with the respective plasma HDL cholesterol levels 
in a given subject. 
Plasma LCAT activity was determined following the general procedure of Glomset 
and Wright with minor modifications as previously published (22;23). In short, 
plasma samples were incubated with labelled [3H]-cholesterol substrate for 6 h at 
37 0C and the reaction was stopped by the addition of cold ethanol to the incubation 
medium. Free and esterified cholesterol were separated using disposable silica 
columns. [3H]-cholesteryl esters were eluted with hexane. Under these experimental 
conditions the plasma cholesterol esterification rate is linear with time and with 
the amount of plasma used in the incubations. LCAT activity, measured using 
a comparable exogenous substrate method, is strongly correlated with its mass 
concentration in plasma (24). LCAT activity was expressed in arbitrary units (AU) as 
the percentage of LCAT activity obtained within pooled plasma from healthy control 
subjects (100 AU is equivalent to 87 nmol cholesterol esterified per ml plasma per h). 
The inter-assay CV of this method is 6%. 
PON-1 enzymatic activity was assayed as its arylesterase activity, i.e. the rate of 
hydrolysis of phenyl acetate into phenol as described previously (25). Arylesterase 
activity is expressed in kilo units (kU) per liter of serum, with 1 U being equivalent to 
1 mmol of phenyl acetate hydrolyzed per min. The inter-assay CV of this measurement 
is 8%. 
Glucose was analyzed with an APEC glucose analyzer (APEC Inc., Danvers, MA). 
HbA1c was measured by high performance liquid chromatography (Bio-Rad, 
Veenendaal, The Netherlands; normal range 4.6-6.1%).
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Statistical analysis
Data are given as mean ± SD and between group differences were compared by 
unpaired t-tests. Because of skewed distribution, triglyceride levels are given 
in median (interquartile range) and were compared by Mann-Whitney U test. 
Differences in proportions of variables were determined by χ2-analysis. Univariate 
correlations were calculated by linear regression analysis using Pearson’s correlation 
coefficients. Multiple linear regression analysis was performed to determine 
independent predictors of the HDL-AOCap as well as the HDL-AOI. Besides age, 
sex and diabetes status, those variables with which HDL-AOCap and HDL-AOI 
were correlated at a P-value < 0.10 in univariate analyses were included as possible 
independent variables. Interactions were assessed in additional analyses. To this end, 
the group mean value of the continuous variable of interest was subtracted from the 
measured value in order to obtain a distribution centered on the mean. Product terms 
between the variables of interest were then calculated. Two-sided P-values  <0.05 
were considered statistically significant. 
 
Results
Clinical characterization of the diabetic patients and the control group
Subjects with type 2 diabetes mellitus were older (p<0.05), while the sex distribution 
was not different from controls (Table I). Twenty-nine diabetic patients (39%) 
were using antihypertensive medication (mostly angiotensin-converting enzyme 
inhibitors, angiotensin II antagonists, diuretics and ß-blockers) compared to none 
of the control subjects (data not shown). Oral hypoglycemic drugs were taken by 
52 (70%) of the diabetic patients (metformin alone, n=15; sulfonylurea alone, n=15; 
both drugs, n=22). Systolic and diastolic blood pressure, BMI, blood glucose and 
HbA1c levels were significantly higher in the diabetic group (Table I).
The anti-oxidative capacity of HDL is unchanged in type 2 diabetes mellitus, but the 
total HDL-mediated anti-oxidative protection is decreased 
Plasma total cholesterol, non-HDL cholesterol and apoB levels were not different 
between diabetic and control subjects (Table I). As expected, plasma triglycerides 
were higher, whereas HDL cholesterol and apoA-I levels were lower in diabetic 
patients. LCAT activity was increased, while PON-1 activity was decreased in 
type 2 diabetes mellitus (Table I). The HDL-AOCap was on average very similar 
in diabetic patients compared to control subjects. However, the HDL-AOI, i.e. the 
HDL-AOCap multiplied by the HDL cholesterol plasma levels, was decreased in 
type 2 diabetes mellitus patients, indicating an overall reduced capacity of diabetic 
HDL to protect against LDL oxidation (Table I). All these differences in lipid and 
lipoprotein-related variables remained significant after age- and sex adjustment. In 
all subjects combined, the HDL-AOCap was higher in men (67 ± 11 %) than in 
women (63 ± 10 %, P= 0.018). However, due to lower HDL cholesterol levels in male 
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subjects the HDL-AOI was lower in men compared to women (82 ± 27 %*mmol/l vs. 
97 ± 28 %*mmol/l, P=0.001). Neither in all subjects combined was the HDL-AOCap 
significantly correlated with HDL cholesterol (r=-0.124, P=0.13) or with apoA-I 
(r=-0.107, P=0.19), nor in diabetic and control subjects separately (data not shown). 
Neither the HDL-AOCap nor the HDL-AOI correlated significantly with age 
(r=0.133, P=0.106 and r=0.078, P=0.35, respectively). Plasma LCAT activity was 
similar in men and women (P=0.71, data not shown), while serum PON-1 activity 
was lower in men than in women (112 ± 39 vs. 124 ± 38 AU, P<0.05).
Impaired anti-oxidative function of HDL correlates with decreased glycemic control 
and increased LCAT activity
In all subjects combined, the HDL-AOCap and the HDL-AOI correlated inversely 
with plasma glucose (Table II) and HbA1c (Table II). Although the HDL-AOcap 
was significantly inversely correlated with glucose in control subjects (tabel II), 
the HDL-AOI did not show a significant correlation with glucose in this group 




(n=74) (N=75) P-value P-valuea
Age (years) 59 ± 9 55 ± 10 0.012
Sex (M/F) 36/39 48/28 0.12
Systolic blood pressure (mm Hg) 144 ± 19 131 ± 20 <0.001 0.001
Diastolic blood pressure (mm Hg) 87 ± 9 82 ± 11 <0.001 0.009
BMI (kg/m2) 28.7 ± 4.9 25.9 ± 3.9 <0.001 <0.001
Glucose (mmol/l) 8.9 ± 2.4 5.6 ± 0.7 <0.001 0.001
HbA1c (%) 6.7 ± 1.1 5.3 ± 0.4 <0.001 <0.001
Total cholesterol (mmol/l) 5.41 ± 0.98 5.69 ± 0.95 0.077 0.12
Non-HDL cholesterol 4.13 ± 1.07 4.20 ± 1.00 0.69 0.72
HDL cholesterol (mmol/l) 1.27 ± 0.38 1.49 ± 0.40 <0.001 0.002
Triglycerides (mmol/l) 1.72 (1.10-2.20) 1.31 (0.87-1.91) 0.048 0.034
ApoB (g/l) 0.94 ± 0.23 0.95 ± 0.23 0.82 0.83
ApoA-I (g/l) 1.34 ± 0.24 1.42 ± 0.22 0.022 0.041
LCAT activity (AU) 114 ± 17 107 ± 13 <0.001 <0.001
PON-1 activity (AU) 106 ± 35 128 ± 39 <0.001 0.001
HDL anti-oxidative capacity (%) 65 ± 10 65 ± 11 0.98 0.57
HDL anti-oxidation index 
(%*mmol/l) 82 ± 27 95 ± 28 0.005 0.005
Data are given as mean ± SD or as median (interquartile range). T2DM: Type 2 diabetes mellitus; 
M: male; F: female; apo: apolipoprotein, AU: arbitrary units. P-valuea: P-value adjusted for age and 
sex.
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High LCAT activity is independently associated with impaired anti-oxidative protection of HDL
Multiple linear regression analysis was carried out to determine whether the 
inverse relationship of the HDL-AOCap and the HDL-AOI with LCAT activity 
was independent of glycemic control and PON-1 activity. In age- and sex-adjusted 
models with the HDL-AOCap as dependent variable and with diabetes status, 
glucose or HbA1c, and LCAT activity as independent variables (i.e. those continuous 
variables with which the HDL-AOCap was univariately correlated at P<0.10) the 
HDL-AOCap was independently and inversely related to LCAT activity as well as 
to glucose or HbA1c (Table III, model A and B). No interactions of LCAT activity 
with glucose (P=0.71) or with HbA1c (P=0.82) on the HDL-AOCap were observed. 
Separate analyses in diabetic and control subjects also showed inverse relationships 
of HDL-AOCap with LCAT activity independent of HbA1c (ß= -0.240, P=0.053 in 
diabetic patients and ß= -0.200, P=0.066 in control subjects).
The HDL-AOI was also inversely related to plasma LCAT activity, independent of the 
positive relationship with PON-1 activity (Table IV). Interestingly, no independent 
(Table II, Figure 1A). However, in diabetic patients, both measures of the capacity 
of HDL to protect against LDL oxidation were correlated inversely with glucose and 
HbA1c (Table II, Figure 1B). In all subjects together and in diabetic patients only, 
the HDL-AOCap was associated inversely with plasma LCAT activity (Table II). The 
HDL-AOI was also inversely related to LCAT activity in the combined groups as well 
as in control and diabetic groups separately (Table II, Figure 1C and D). While there 
was no significant relation of the HDL-AOCap with serum PON-1 activity, the HDL-
AOI was related positively with this variable (Table II). 
Table II. Univariate correlations of the HDL anti-oxidative capacity and the HDL anti-oxidation 
index with fasting plasma glucose, HbA1c, lecithin-cholesterol acyltransferase (LCAT) activity 
and paraoxonase-1 (PON-1) activity in all subjects combined and type 2 diabetes mellitus 
patients and control subjects separately
All subjects 
(n=149 )























Plasma glucose -0.157a -0.295d -0.398d -0.322c -0.211a 0.105
HbA1c -0.149a -0.237c -0.330c -0.235b 0.032 0.122
LCAT activity -0.240c -0.349d -0.313c -0.324c -0.175 -0.312c
PON-1 activity -0.049 0.228c -0.075 0.221a -0.030 0.135
Pearson’s correlation coefficients are given. aP<0.10; bP<0.05; cP≤0.01; dP≤0.001.
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effect of diabetes status was observed taking glucose or HBA1c into account. LCAT 
activity did not interact with glucose (P=0.14) or with PON1 activity (P=0.44) on the 
HDL-AOI. Additional adjustment for the use of anti-hypertensive drugs and for the 
use of metformin and sulfonylurea did not confound the independent relationships 
r = 0.105, n.s.
r = -0.312, P≤0.01
r = -0.322, P≤0.01
r = -0.324, P≤0.01
Figure 1. Univariate relationships of the HDL anti-oxidative index with fasting plasma glucose 
levels and LCAT activity.  Panels A and B show univariate relationships of the HDL anti-oxidative 
index (HDL-AOI) with glucose while panels C and D show univariate relationships of the HDL-AOI 
with LCAT activity in 75 control subjects (circles, panels A and C) and 74 type 2 diabetic patients 
(triangles, panels B and D).
Table III. Multiple linear regression analyses showing relationships of the anti-oxidative capacity 
of HDL with diabetes status, glucose or HbA1c and plasma lecithin-cholesterol acyltransferase 
(LCAT) activity in 74 type 2 diabetic patients and 75 control subjects (n=149)
Model A Model B
B (SE) ß P-value B (SE) ß P-value
Diabetes (yes/no) 3.35 (2.31) 0.157 0.15 3.10 (2.21) 0.145 0.16
Plasma glucose -1.10 (0.52) -0.245 0.036
HbA1c -2.36 (1.09) -0.232 0.031
LCAT activity -0.12 (0.059) -0.171 0.048 -0.13 (0.056) -0.193 0.021
All models are adjusted for age and sex. Model A includes diabetes status, plasma glucose, 
and LCAT activity; model B includes includes diabetes status, HbA1c, and LCAT activity. B (SE): 
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of the HDL-AOCap with LCAT activity (ß= -0.190, P=0.028 in a model which 
included glucose and ß= -0.224, P=0.007 in a model which included HbA1c). The 
inverse relationship of the HDL-AOI with LCAT activity also remained significant 
after adjusting for the use of anti-hypertensive drugs and the use of metformin and 
sulfonylurea (ß= -0.326, P<0.001 in a model including glucose; ß= -0.354, P<0.001 
in a model including HbA1c).
 
Discussion
The results of this study indicate that the overall anti-oxidative protection capacity 
exerted by HDL is decreased in type 2 diabetes mellitus patients. These findings can 
largely be ascribed to significantly lower plasma HDL cholesterol levels in diabetics, 
since the anti-oxidative protection of HDL was comparable between diabetic patients 
and controls in assays normalizing for HDL cholesterol. In addition, our overall data 
suggest that increased LCAT activity, hyperglycemia and decreased PON-1 activity 
are important factors determining a decreased anti-oxidative functionality of HDL. 
The major underlying aim of the present study was to determine whether the 
anti-oxidative functionality of HDL from type 2 diabetes mellitus patients differs 
from healthy subjects. Our data indicate that the anti-oxidative function of HDL 
from these patients is similar to control individuals in an assay that uses the 
same amounts of HDL cholesterol. Notably, when the significantly lower plasma 
HDL cholesterol levels of patients with diabetes are taken into account, as for the 
calculated HDL-AOI, type 2 diabetes mellitus patients have a significantly reduced 
total anti-oxidative capacity attributable to HDL. In our view, calculating HDL-AOI 
Table IV. Multiple linear regression analyses showing relationships of the HDL anti-oxidation 
index with diabetes status, glucose or HbA1c, plasma lecithin-cholesterol acyltransferase (LCAT) 
activity, and serum paraoxonase-1 (PON-1) activity in 74 Type 2 diabetic patients and 75 control 
subjects (n=149)
Model A Model B
B (SE) ß P-value B (SE) ß P-value
Diabetes (yes/no) -0.26 (5.75) -0.005 0.96 -3.72 (5.51) -0.067 0.50
Plasma glucose -1.92 (1.26) -0.164 0.13
HbA1c -1.75 (2.63) -0.066 0.51
LCAT activity -0.52 (0.14) -0.290 <0.001 -0.57 (0.14) -0.320 <0.001
PON-1 activity 0.12 (0.055) 0.168 0.029 0.12 (0.055) 0.162 0.036
All models are adjusted for age and sex. Model A includes diabetes status, plasma glucose, LCAT 
activity and PON-1 activity; model B includes includes diabetes status, HbA1c, LCAT activity and 




by multiplying the HDL-AOCap with the individual plasma HDL cholesterol levels 
is both clinically justified and meaningful as a reflection of an individuals total anti-
oxidative protection exerted by HDL. From a methodological point of view we chose 
for an endpoint assay to determine the anti-oxidative function of HDL. Such a set-up 
would be easier for application as a clinical test for the screening of large numbers of 
individuals than a dynamic assay. 
Our findings differ in several aspects from the conclusions of a previous study 
that reported the anti-oxidative function of HDL to be impaired using a similar 
methodological approach, but including lower numbers of patients and control 
subjects (26). These authors reached the conclusion that the functional impairment 
was due to decreased PON-1 activity as the major contributing factor. In our study, 
type 2 diabetes mellitus patients also had significantly decreased PON-1 activity 
compared with controls. While lower PON-1 activity predicted an impaired 
HDL-AOI, it was, however, not significantly associated with the HDL-AOCap. 
In the previous report, also no correlation of plasma glucose levels with the anti-
oxidative properties of HDL was seen, while a high LCAT activity was associated 
with an improved anti-oxidative function of HDL, which is opposite to our results 
(26). Overall, the diabetes-associated dyslipidaemia was more pronounced in this 
previous study compared with our type 2 diabetes mellitus group, since plasma 
triglycerides were more than two-fold elevated (26), while only being approximately 
30% higher in the diabetic patients included in our study. These differences might 
have conceivably translated into altered anti-oxidative functionality of HDL in the 
previous report (27).
Our data also demonstrate that increased blood glucose and HbA1c levels as long-
term parameter of glycemic control were independently related to impaired HDL 
anti-oxidative function. Hyperglycaemia is known to result in non-enzymatic 
glycation of various plasma proteins. Consistently, glycation of HDL-associated 
proteins, especially apoA-I, impairs their functional activities, which was thus far 
mostly demonstrated for cholesterol efflux (28) and anti-inflammatory properties 
of HDL (29). Therefore, it is highly plausible that the independent correlation of 
decreased anti-oxidative function of HDL with parameters of hyperglycemia reflects 
a pathophysiologically relevant causal relationship.
However, the most striking difference between our present study and previous work 
remains the independent association of higher LCAT activity with decreased HDL 
anti-oxidative function. LCAT plays an important role in HDL metabolism mediating 
the formation of larger HDL particles. Consequently, the catabolic rate of apoA-I is 
substantially increased in subjects with genetic LCAT deficiency resulting in very 
low plasma HDL levels. Data from animal models using overexpression or ablation 
of LCAT are consistent with this effect of LCAT on HDL metabolism (30-35). Since 
increased LCAT activity results in increased plasma HDL cholesterol levels, LCAT is 
classically believed to be atheroprotective. Nonetheless, the experimental and clinical 
evidence for such a role of LCAT is less clear. Overexpression of LCAT resulted in 
unchanged or even increased atherosclerosis in mice (30;31;33;34), while a reduction 
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in atherosclerotic lesion formation was seen in rabbits (36). On the other hand, 
LCAT deficiency in mice resulted in reduced atherosclerosis despite low plasma HDL 
cholesterol levels in two studies (32;35), while another report suggested increased 
atherosclerotic lesion formation (37). In humans, the impact of LCAT deficiency on 
atherosclerosis has been investigated in a limited number of studies. However, despite 
reduced plasma HDL cholesterol levels, increased atherosclerosis is not immediately 
apparent in subjects with genetic reduction or complete deficiency of LCAT (38;39). 
Using intima media thickness (IMT) as a read-out for subclinical atherosclerosis, one 
study indicated that partial LCAT deficiency is associated with increased IMT (40), 
while, in contrast, another report even suggested a gene-dose-dependent reduction 
in IMT in LCAT deficiency states (41). Consistent with these latter results, increased 
plasma LCAT activity in metabolic syndrome subjects was associated with increased 
IMT (22). In a recent report from the PREVEND cohort we could also not confirm 
an inverse association of plasma LCAT activity with cardiovascular risk (23). In 
that study, higher LCAT activity even appeared to abolish the reduced CVD risk 
associated with higher plasma HDL cholesterol levels. Additionally, in a population-
based nested case-control study from the EPIC-Norfolk population, LCAT mass 
levels were not associated with coronary heart disease risk (42). Interestingly, though, 
women with high plasma LCAT mass levels had an increased CVD risk in that report 
(42). These combined data indicate that also in humans an atheroprotective role for 
LCAT is not unequivocally established. 
The mechanisms responsible for the negative impact of LCAT on HDL anti-oxidative 
functionality are not precisely understood at present. Among other possibilities, 
LCAT might contribute to the generation of oxidative stress, which is believed to play 
a key role in the initiation and propagation of atherosclerotic lesions (43). Although 
LCAT has been shown to have anti-oxidative properties in vitro (44), the LCAT 
reaction in vivo conceivably contributes to the generation of oxygen radicals and 
oxidative stress, which is exemplified by an impressive reduction of oxidative stress in 
apoE knockout mice lacking LCAT (35). Conceivably, increased LCAT-dependent in 
vivo oxidative stress could be linked to the inverse correlation between LCAT activity 
and the HDL-AOCap in our present study. Further mechanistic studies including 
animal models are required to further investigate a causative impact of LCAT on 
HDL function.
In a more general point of view a potential limitation of our current cross-sectional 
study is that no conclusions regarding cause-effect relationships can be drawn. In 
addition, the present report does not address a potential prospective role of HDL 
anti-oxidative functionality for e.g. the incidence of cardiovascular disease or the 
progression of diabetes mellitus in the groups investigated. Furthermore, next to the 
factors impacting on the HDL anti-oxidative capacity investigated in the current study, 
there are other HDL-associated anti-oxidative proteins such as PAF-AH (Lp-PLA2) 
that might also contribute to the protective effect of HDL against LDL oxidation (45). 
It might also be important to explicitly point out that with the introduction of the 
HDL-AOI the lower HDL-C levels in the diabetic patients become again clinically 
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relevant as a factor influencing the total anti-oxidative protection conferred by HDL. 
Also, in contrast to previous work (26), this study did not address the differential 
contribution of HDL subpopulations such as HDL2 and HDL3. However, with 
respect to this latter point we feel that, although mechanistically interesting, most 
relevant in a clinical setting is the total anti-oxidative protection conferred by HDL 
as determined in the present study. 
In summary, our data suggest that increased LCAT activity as well as elevated blood 
glucose levels independently contribute to the functional impairment of the anti-
oxidative properties of HDL. While the HDL-AOCap did not differ between groups, 
the overall HDL-mediated anti-oxidative protection was decreased in type 2 diabetes 
mellitus due to lower plasma HDL cholesterol levels. As a therapeutic perspective, 
the present study emphasizes the importance of adequate glycemic control for HDL 
function. Interventions aimed to increase plasma HDL levels in diabetic patients 
without increasing LCAT activity could prove a successful strategy to restore the 
decreased total anti-oxidative protection by HDL.
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